| Name | Title | Contact Details |
|---|
e-MedRecords is a Sparta, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Orb® Platform automatically syncs health data from your doctor and your apps and wearable devices so you can own it, gives you context so can understand it and helps you improve it so you can transform. For consumers and patients, the Orb® Platform is a cloud-based health management platform that syncs and stores your personal health data from multiple doctor’s offices as well as your apps and wearable devices. On your computer or mobile device, Orb provides you with instant clarity and understanding behind your data while also providing actionable insight and solutions to help improve your health. For providers, the Orb® Platform enables physicians to have more oversight and understanding of their patient populations. Orb connects with both the provider’s current lab networks and/or electronic health record systems as well as the patients` external lab networks to support providers with comprehensive insights into the patient’s lab data. The Orb® Platform also enables providers to quickly identify, contact and support at-risk patient populations. Orb Health has strategically established data connectivity to 120 laboratory networks, 30 EMR platforms, and over 150 wearable devices and apps.
With a track record of transformative leadership in healthcare technology, Figueroa will spearhead our efforts to integrate cutting-edge technology, streamline operations, and enhance patient care across our extensive network of community-based clinics.As a dynamic leader, Figueroa brings a wealth of experience in leveraging technology to optimize healthcare delivery. His strategic vision aligns perfectly with our commitment to providing the best possible care to our patients. He will play a pivotal role in advancing our digital infrastructure, fostering innovation, and ultimately, improving outcomes for those we serve.
Validation Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.